Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial

J.A. Walsh, M.N. Magrey, X. Baraliakos, K. Inui, M.Y. Weng, E. Lubrano, D. van der Heijde, A. Boonen, L.S. Gensler, V. Strand, J. Braun, T. Hunter, X.Q. Li, B.J. Zhu, L. Leon, D.M.S. Calderon, U. Kiltz*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Web of Science)
Original languageEnglish
Pages (from-to)451-460
Number of pages10
JournalArthritis Care and Research
Volume74
Issue number3
Early online date26 Jan 2022
DOIs
Publication statusPublished - Mar 2022

Keywords

  • PATIENT-REPORTED OUTCOMES
  • ANKYLOSING-SPONDYLITIS
  • MONOCLONAL-ANTIBODY
  • CERTOLIZUMAB PEGOL
  • DOUBLE-BLIND
  • CRITERIA
  • ETANERCEPT
  • EFFICACY

Cite this